Should I buy Certara, Inc. (CERT) stock or is it too late?

Certara, Inc. · Health Care · price $8
Logo Certara, Inc.See the full Certara, Inc. (CERT) profile
⭐ What the most reliable analysts say

No reliable analyst is bullish on this stock right now. A “reliable” analyst is a firm that, on this sector, hits more than 55% of its targets and beats its sector. None of them sees upside here — which is exactly why this stock is in no JPI selection.

Firm-by-firm track record on Certara, Inc.

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.
Firm% rightGain vs sectorCallsAims for
Barclays25 %-16.5 %8$8 -11%
Credit Suisse0 %-14.9 %5
In short — Should you invest in Certara, Inc.? Is it too late, still worth it? Analysts are split (29% buy, median target $8, i.e. -5%). But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

  • Few solid positives from analysts right now: of 7 ratings, only 2 buys, and the median price target ($8) is -5% below the price ($8). Caution prevails.

⚠️ Reasons to hesitate

  • Even the most reliable firm on CERT, Barclays (25% hit rate, 8 scored calls), only targets $8 (call made on August 5, 2026, maturing on August 5, 2027) (-11%) in its most recent call, and $16 (call made on October 2, 2025, maturing on October 2, 2026) (+90%) in the one coming due soonest. The stock may already have run past its target.
  • The consensus is not unanimous: of 7 ratings, 5 are neutral.
  • Limited upside: the median target is only -5% from the current price.
  • A 12-month target is not a guaranteed path: the price can fall in the meantime.
  • No dividend: your return depends only on price appreciation.

The analyst consensus on CERT

Median target $8 (-5%) · 7 ratings · Hold consensus

Strong Buy00%
Buy229%
Hold571%
Sell00%
Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Certara, Inc. now?

We won't decide for you. The facts: 29% of analysts rate it a buy, median target $8 (-5%), and Barclays (most reliable on CERT, 25%) targets $8. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Certara, Inc.?

The stated upside is small: the median target ($8) sits just -5% from the price ($8) (most reliable on CERT: Barclays, 25%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Certara, Inc. still worth investing in?

It depends on the gap between the price ($8) and its estimated value: analysts target $8 on median (-5%), with 29% buys (most reliable on CERT: Barclays, 25%). Cross-check with their real reliability on CERT and the cautions above. Information, not advice.

What's the main risk in buying CERT?

Even the most reliable firm on CERT, Barclays (25% hit rate, 8 scored calls), only targets $8 (call made on August 5, 2026, maturing on August 5, 2027) (-11%) in its most recent call, and $16 (call made on October 2, 2025, maturing on October 2, 2026) (+90%) in the one coming due soonest. The stock may already have run past its target.

→ Go deeper: the full Certara, Inc. profile (consensus, analyst reliability, price target, performance).

JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool’s data · not financial advice · full version (free)